A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes

[1]  A. Matsunaga,et al.  A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka , 2018, Clinical nephrology. Case studies.

[2]  A. Shimizu,et al.  Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2 , 2018, Case Reports in Nephrology and Dialysis.

[3]  T. Miyata,et al.  A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate , 2017, Case Reports in Nephrology and Dialysis.

[4]  Irina Florina Tudorache,et al.  Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features , 2017, Computational and structural biotechnology journal.

[5]  H. Nakashima,et al.  Topics in lipoprotein glomerulopathy: an overview , 2014, Clinical and Experimental Nephrology.

[6]  T. Mochizuki,et al.  Glomerulopathy with Homozygous Apolipoprotein E2: A Report of Three Cases and Review of the Literature , 2013, Case Reports in Nephrology and Dialysis.

[7]  Tariq Ahmad Masoodi,et al.  Screening and Evaluation of Deleterious SNPs in APOE Gene of Alzheimer's Disease , 2012, Neurology research international.

[8]  M. Caslake,et al.  Apolipoproteins: metabolic role and clinical biochemistry applications , 2011, Annals of clinical biochemistry.

[9]  Jianglei Chen,et al.  Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions , 2011, Proceedings of the National Academy of Sciences.

[10]  Radiya M. Sojitrawala,et al.  A monomeric, biologically active, full-length human apolipoprotein E. , 2007, Biochemistry.

[11]  S. Oikawa,et al.  Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  K. Weisgraber,et al.  Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization DOI 10.1194/jlr.M200157-JLR200 , 2002, Journal of Lipid Research.

[13]  V. Narayanaswami,et al.  Lipid association-induced N- and C-terminal domain reorganization in human apolipoprotein E3. , 2001, The Journal of biological chemistry.

[14]  I. Sakata,et al.  Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. , 2001, Kidney international.

[15]  T. Kita,et al.  A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. , 1999, Kidney international.

[16]  J. Sasaki,et al.  Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy. , 1997, Journal of the American Society of Nephrology : JASN.

[17]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.